Author

Mary F. Paine

Washington State University SpokaneORCID 0000-0002-3331-1839Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:clinical cohort / trial· 1 Approach:experimental assay· 1 Assay:metabolomics· 1 Approach:statistical model· 1

Frequent Co-Authors

Aarzoo ThakuriD· 2 shared Bhagwat PrasadiD· 2 shared Dilip Kumar SinghiD· 2 shared Andrea GaedigkiD· 1 shared Anoud Sameer Ailabouni· 1 shared Emese Kis· 1 shared Erin C. BooneiD· 1 shared John ClarkeiD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

Aarzoo ThakurORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Pharmacology & ToxicologyClinical Pharmacology & TherapeuticsPeer-reviewedMay 22, 2025

From discovery to translation: Endogenous substrates of OAT1 and OAT3 as clinical biomarkers for renal secretory function

Aarzoo Thakur, Dilip Kumar Singh, Katherine D. Hart…·Bhagwat Prasad

This paper identifies 23 endogenous substrates of OAT1/3 as clinical biomarkers for renal secretory function, enabling prediction of drug interactions and interindividual variability.

13 citationstop 3%

humanmetabolomics

𝕏 PostBluesky

Pharmacology & ToxicologyClinical Pharmacology & TherapeuticsPeer-reviewedMar 17, 2025

Quantitative contributions of hepatic and renal organic cation transporters to the clinical pharmacokinetic cimetidine-metformin interaction

Anoud Sameer Ailabouni, Dilip Kumar Singh, Aarzoo Thakur…·Bhagwat Prasad

This study investigates how cimetidine affects metformin's pharmacokinetics by inhibiting OCT1 and OCT2, showing increased plasma exposure and reduced renal clearance.

11 citationstop 4%

humanclinical cohort / trial

𝕏 PostBluesky